December 18, 2025
Shardul Amarchand Mangaldas & Co. (SAM) advised Nephrocare Health Services Limited (“Nephroplus”) on its initial public offering aggregating to approximately US$ 95.99 million (₹ 8,710.48 million), comprising a fresh issue of ₹ 3,534.05 million and an offer for sale of ₹ 5,176.43 million.
SAM acted as legal counsel to Nephroplus on Indian law aspects of the transaction, advising on the drafting and regulatory compliance for the IPO, including coordination with multiple domestic and international stakeholders and supporting the company through the prospectus filing and listing process.
The SAM team was led by Prashant Gupta, National Practice Head – Capital Markets and Devi Prasad Patel, Partner; and assisted by Divya Dhawan, Associate; Satakshi N. Dixit, Associate; and Arjun Bhatia, Associate.
The Bar Council of India does not permit solicitation of work and advertising by legal practitioners and advocates. By accessing the Shardul Amarchand Mangaldas & Co. website (our website), the user acknowledges that:
Click here for important public notice from the Firm.